Ketchum Emily Behren, Clarke Andrea, Clemmons Amber B
Augusta University Medical Center, Augusta, Georgia.
J Adv Pract Oncol. 2022 Jan;13(1):77-85. doi: 10.6004/jadpro.2022.13.1.7. Epub 2022 Feb 1.
Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of plasma cells with or without production of monoclonal immunoglobulins. Management of patients with MM begins with induction therapy, typically a proteasome inhibitor (PI) with dexamethasone and an immunomodulator (IMID), followed by autologous hematopoietic stem cell transplantation in eligible patients. Although various treatments are available, MM is considered incurable, and patients with progression after multiple treatment lines, including CD38 monoclonal antibodies, have a median overall survival of 8.6 months. Belantamab mafodotin-blmf (Blenrep) is a first-in-class antibody-drug conjugate directed against B-cell maturation antigen (BCMA) that obtained U.S. Food and Drug Administration accelerated approval in August 2020 for patients with multiply relapsed/refractory MM. This article provides information on the mechanism of action, efficacy, safety, monitoring, and current place in therapy for belantamab mafodotin-blmf.
多发性骨髓瘤（MM）是一种血液系统恶性肿瘤，其特征为浆细胞增殖，可伴有或不伴有单克隆免疫球蛋白的产生。MM患者的治疗始于诱导治疗，通常是使用蛋白酶体抑制剂（PI）联合地塞米松和一种免疫调节剂（IMID），随后对符合条件的患者进行自体造血干细胞移植。尽管有多种治疗方法可用，但MM被认为是无法治愈的，在包括CD38单克隆抗体在内的多条治疗线后病情进展的患者，中位总生存期为8.6个月。贝兰他单抗马福多汀-blmf（Blenrep）是一种针对B细胞成熟抗原（BCMA）的一流抗体药物偶联物，于2020年8月获得美国食品药品监督管理局加速批准，用于治疗多次复发/难治性MM患者。本文提供了有关贝兰他单抗马福多汀-blmf的作用机制、疗效、安全性、监测及当前在治疗中的地位的信息。
